Curriculum
Module 02 · 45 min

Vasomotor Symptoms: KNDy Neurons and the Thermoneutral Zone

Hot flushes are a hypothalamic thermoregulatory event — and that mechanism is now a drug target.

Endocrine & MHTBrain, mood & sleepPrimary care track
Module progress0%
Quiz 0/3Cards 0/5Claims 0/5
Learning objectives

By the end of this module you will be able to

  • L01Describe the KNDy neuron hypothesis and explain how NK3 antagonism relieves hot flushes without oestrogen.
  • L02Quote the SWAN median total VMS duration and the four trajectory subtypes.
  • L03Explain why frequent or persistent VMS is associated with adverse cardiovascular and cognitive markers.
  • L04Choose an appropriate outcome measure (frequency and severity over 4 weeks) when assessing treatment response.
  • L05Counter the belief that VMS 'only last a year or two'.
Scope

Topics covered

01Physiology of the thermoneutral zone and its narrowing after estradiol withdrawal
02KNDy (kisspeptin/neurokinin B/dynorphin) neurons in the arcuate nucleus
03NK3 receptor signalling and the MPOA thermoregulatory pathway
04Natural history: duration, trajectory subtypes from SWAN
05VMS as a cardiovascular and cognitive risk marker
06Objective measurement: sternal skin conductance vs symptom diaries
Module narrative

How this plays out in practice

Primary care view· your track

Quantify VMS before and after treatment: number of moderate-to-severe episodes per 24 hours plus a nocturnal count. Tell women the honest duration figures — a median of over seven years — because unrealistic expectations drive premature treatment discontinuation. Frequent VMS is not merely a quality-of-life issue; flag these women for cardiovascular risk assessment.

Specialist view

Use trajectory subtypes to plan duration of therapy: early-onset persistent flushers need a long-horizon plan, not a 12-month course. In refractory cases confirm the diagnosis before escalating — carcinoid, phaeochromocytoma, thyrotoxicosis, mastocytosis, medullary thyroid carcinoma and drug causes (tamoxifen, aromatase inhibitors, GnRH agonists, SSRIs on withdrawal, niacin, opioids) all mimic VMS.

Advanced note

The KNDy model rests on convergent evidence: arcuate KNDy neuron hypertrophy in postmenopausal women, NKB infusion inducing flushes in healthy volunteers (Jayasena 2015), and phase 3 NK3 antagonist efficacy (SKYLIGHT 1/2 for fezolinetant, OASIS 1–3 for elinzanetant). Elinzanetant's dual NK1/NK3 antagonism gives an additional sleep signal, consistent with NK1 involvement in arousal circuitry — a useful natural experiment separating thermoregulatory from sleep effects.

Expected takeaways

What you should walk away believing

  • →Median total VMS duration in SWAN was 7.4 years; women whose symptoms begin in the early transition average over 11 years.
  • →Estradiol withdrawal — not the absolute level — narrows the thermoneutral zone; this is why abrupt MHT cessation triggers rebound flushing.
  • →KNDy neurons hypertrophy when oestrogen negative feedback is lost; NK3 antagonists (fezolinetant, elinzanetant) act on this circuit directly.
  • →Persistent VMS correlates with worse endothelial function, greater carotid intima-media thickness and higher subclinical CVD burden — it may be a marker, not just a nuisance.
Myth-buster

What patients — and colleagues — get wrong

The claim

“Hot flushes are caused by low oestrogen, so the level tells you how bad they'll be.”

Reality

Serum estradiol correlates poorly with VMS severity. Withdrawal dynamics and central sensitivity — mediated through KNDy neuron activity and the narrowed thermoneutral zone — matter far more than the static level. Women with identical estradiol levels can have zero or fifty flushes a day.

Graded claims

Evidence grading for this module

A

Median total VMS duration exceeds 7 years

Established — RCT / guideline-grade — SWAN, Avis et al. JAMA Intern Med 2015 — 7.4 years median, 4.5 years post-FMP.

A

NK3 receptor antagonism reduces moderate-severe VMS frequency vs placebo

Established — RCT / guideline-grade — SKYLIGHT and OASIS phase 3 programmes.

B

Frequent VMS is associated with subclinical cardiovascular disease markers

Supported in defined populations — SWAN Heart, MsHeart cohorts — consistent association; causality unproven.

E

Serum estradiol level predicts individual VMS severity

Popular, weak or conflicting support — Weak and inconsistent correlation.

E

Black cohosh reliably reduces moderate-to-severe VMS

Popular, weak or conflicting support — Meta-analyses are heterogeneous and largely null against placebo; hepatotoxicity case reports exist.

Evidence summary

Graded claims, key takeaways and sources for this module.

Open printable summary
Clinical vignettes

Apply it in clinic

'I was told it lasts a year'

A 53-year-old, 3 years post-FMP, has 12 moderate-severe flushes daily and wakes 4 times nightly. She stopped MHT after 9 months because 'it should be over by now' and symptoms returned within days.

What is the priority in this consultation?

Self-assessment

Check your recall

Q1

Which neuronal population is implicated in the genesis of hot flushes?

Q2

In SWAN, median total duration of frequent VMS was approximately:

Q3

A 55-year-old with flushing, diarrhoea and wheeze. What should you exclude before labelling VMS?

Flashcards

Retrieval practice

Card 1 / 5
Reviewed 0 / 5
Glossary

Terms used in this module

Vasomotor symptomsVMS
Hot flushes and night sweats — episodic heat dissipation responses driven by hypothalamic thermoregulatory dysfunction.
Thermoneutral zone
The core temperature range within which neither sweating nor shivering occurs; narrowed in symptomatic women.
NK3 receptor
Neurokinin-3 receptor, the target of neurokinin B on KNDy neurons; blockade reduces flush frequency.
Primary sources

Read the evidence yourself